The intestinal mucosa serves as both a conduit for uptake of food-derived 20 nutrients and microbiome-derived metabolites and as a barrier that prevents 21 tissue invasion by microbes and tempers inflammatory responses to the myriad 22 contents of the lumen. How the intestine coordinates physiological and immune 23 responses to food consumption to optimize nutrient uptake while maintaining 24 barrier functions remains unclear. Here, we describe how a gut neuronal signal 25 triggered by food intake is integrated with intestinal antimicrobial and metabolic 26 responses controlled by type 3 innate lymphoid cells (ILC3) 1-3 . Food consumption 27 rapidly activates a population of enteric neurons that express vasoactive 28 intestinal peptide (VIP) 4 . Projections of VIP-producing enteric neurons (VIPen) in 29 the lamina propria are in close proximity to clusters of ILC3 that selectively 30 express VIP receptor type 2 (VIPR2 or VPAC2). ILC3 production of IL-22, which is 31 up-regulated by commensal microbes such as segmented filamentous bacteria 32 (SFB) 5-7 , is inhibited upon engagement of VIPR2. As a consequence, there is a 33 reduction in epithelial cell-derived antimicrobial peptide, but enhanced 34 expression of lipid-binding proteins and transporters 8 . During food consumption, 35 activation of VIPen thus enhances growth of epithelial-associated SFB and 36 increases lipid absorption. Our results reveal a feeding-and circadian-regulated 37 dynamic intestinal neuro-immune circuit that promotes a trade-off between innate 38 immune protection and efficiency of nutrient absorption. As intestinal pathogenic 39 microbes disrupt this neuro-immune inhibitory axis, targeting this pathway may 40 enhance intestinal barrier function to prevent invasion by enteropathogens 2,3,9 . 41 3 42
. The activation of ILC3 is regulated by cytokines, including IL-23, and TL1A, 48 which are produced by mononuclear phagocytes and induced by intestinal microbe-49 derived stimuli 5, 7, 11 . Cytokines produced by activated ILC3, particularly IL-22, support 50 the production of antimicrobial peptides (e.g. RegIIIg) and mucin by IECs, ensuring 51 spatial segregation of microbes from the intestinal tissue 12, 13 . This microbiota-ILC3-IEC 52 circuit promotes intestinal barrier function by controlling intestinal commensal microbiota 53 and mediating rapid protective responses to enteropathogens 2, 3, 9, 12 . Different subtypes 54 of ILC3s are present within the intestinal lamina propria and are dispersed or in tertiary 55 lymphoid tissue clusters known as cryptopatches (CPs) and isolated lymphoid follicles 56 (ILFs) 14, 15 . In perusing transcriptomic datasets of small intestinal ILCs, we noticed in 57 CCR6 + ILC3, which comprise the lymphoid tissue inducer (LTi) cells enriched in CPs 58 and ILFs, selective expression of multiple neurotransmitter/neuropeptide receptors and 59 genes related to axonal guidance and neuron differentiation when compared to CCR6 neg 60 ILC3 and NCR + ILC3 ( Fig. 1a and Extended Data Fig. 1a-c) 16, 17 . This prompted us to 61 evaluate whether CCR6 + ILC3 in the intestinal lamina propria were associated with 62 neuronal projections from the enteric nervous system (ENS). The ENS is part of the 63 peripheral autonomic nervous system, which controls gastrointestinal functions by 64 promoting rapid gut responses to changes in the luminal compartment (e.g. food intake, 65 microbes, metabolites, etc. [18] [19] [20] [21] [22] ). We observed that ILC3 in CPs/ILFs were in close 66 proximity to neuronal projections in the lamina propria ( Fig. 1b-d 
and Supplementary 67
Videos 1,2). The CP/ILF-associated neuronal projections were positive for vasoactive 68
intestinal peptide upon staining with specific antibody (VIP, Fig. 1e and Extended Data 69 Fig. 2 ). We also observed association of VIPen and colonic lymphoid patches 70 (Extended Data Fig. 3a,b ). Indeed, ILC3 in CPs/ILFs were closer to VIP + enteric 71 neurons (VIPen) than to neurons positive for substance P or tyrosine hydroxylase 72 (which produce norepinephrine or dopamine) ( Fig. 1f and Extended Data Fig. 2 ). These 73 anatomical findings, together with the fact that CCR6 + ILC3 express a high amount of 74 VIP receptor type 2 (Vipr2) (Fig. 1a ), prompted us to investigate whether signaling from 75
VIPen could modulate CCR6 + ILC3 functions and intestinal immune homeostasis. 76
We isolated ILC3 from the lamina propria of the small intestine of C57BL/6 mice 77 (Extended Data Fig. 4a ) and observed that in vitro activation of VIPR2 inhibited IL-23-78 induced production of IL-22 by CCR6 + ILC3 (Fig. 2a,b and Extended Data Fig. 4b,c) , 79
although there was no effect on cell activation (marked by Sca-1 up-regulation) or on IL-80 22 production by CCR6 neg ILC3 (Extended Data Fig. 4d-f ). In order to investigate the in 81 vivo role of VIPR2 activation in CCR6 + ILC3 functions, we generated mixed bone 82 marrow chimeric mice reconstituted with a 1:1 ratio of isotype-marked Vipr2 +/+ and 83 Vipr2 −/− cells. IL-22 was expressed in a greater proportion of Vipr2 −/− CCR6 + ILC3 when 84 compared to Vipr2 +/+ ILC3 (Extended Data Fig 5a,b) . We also generated mice with 85 conditional deletion of the gene encoding VIPR2 in ILC3 (Rorc(t) Cre Vipr2 fl/fl , or ILC3 D Vipr2 ) 86 and found that a larger proportion and number of CCR6 + ILC3 isolated from the small 87 intestine of ILC3 D Vipr2 mice expressed IL-22 than cells isolated from WT littermates (Fig. 88 2c and Extended Data Fig. 5c-f ). Epithelial RegIIIg mRNA, regulated by was 89 considerably higher in IECs from ILC3 D Vipr2 mice when compared to WT mice (Fig. 2d) , 90
suggesting that VIPen-derived neuropeptide acts through VIPR2 to inhibit ILC3-91 mediated innate immune responses. 92
To determine whether direct modulation of VIPen (inhibition or activation) could 93 affect ILC3 function, we adopted a chemogenetic strategy utilizing mice engineered to 94 express designer receptors exclusively activated by designer drugs (DREADD) 23 . We 95 selectively expressed inhibitory DREADD (hM4Di) in VIPen of Vip IRES-Cre hM4Di fl-stop-fl/+ 96 mice and observed a higher frequency of IL-22-producing CCR6 + ILC3 at 24h following 97
VIPen inhibition with the DREADD ligand clozapine-N-oxide (CNO, Fig. 2e,f) . In parallel, 98 there was increased RegIIIg mRNA expression in the IECs after VIPen inhibition ( Fig.  99 2g). Conversely, mice expressing the activating DREADD (hM3Dq) in VIPen (Vip IRES-100 Cre hM3Dq fl-stop-fl/+ mice) had fewer IL-22 + cells among the CCR6 + ILC3 and lower RegIIIg 101 mRNA in IECs following VIPen activation with CNO ( Fig. 2h-j) . Combined, these results 102 indicate that VIPen modulates intestinal immune homeostasis, acting through VIPR2 on 103 CCR6 + ILC3 to inhibit cell activation and IL-22 production. 104
We next investigated whether alteration of VIPen activity contributes to changes of 105 intestinal barrier function during intestinal colonization with an enteropathogen. As 106 previously described 24 , following infection with Citrobacter rodentium there was 107 increased Vip mRNA expression in the proximal colon and cecum and of VIP amounts 108 in the portal vein, but not in the peripheral blood (Extended Data Fig. 6a -c), suggesting 109 6 an increase in VIPen activity in the intestinal tissue. Oral gavage of mice with a 110 relatively low dose of C. rodentium (2x10 9 CFU) is tolerated by mice with an intact 111 immune system. However, DREADD-mediated activation of VIPen during the first 4 112 days of infection led to increased bacterial translocation to the spleen and liver ( Fig.  113 2k,l) and resulted in reduced survival (Fig. 2m ), despite only a moderate increase in the 114 amount of luminal C. rodentium (Extended Data Fig. 6d ). Gavage with a high dose of C. 115 rodentium (4x10 10 CFU) resulted in large amounts of bacteria that translocated to the 116 liver and spleen (9d.p.i.) ( Fig. 2n VIPen on mortality and bacterial translocation (Extended Data Fig. 6f ,g) Activation of 121
VIPen during the events that follow infection with enteropathogens may therefore be an 122 important contributor to intestinal barrier breakdown, which could be mitigated by 123 inhibition of enteric VIP activity on ILC3. 124
These results suggested the existence of physiological signals that promote 125 activation of VIPen during homeostasis, with consequent tonic inhibition of CCR6 + ILC3. 126
Food ingestion has been reported to rapidly signal VIP release in the intestine 4 . Indeed, 127
we observed a greater amount of VIP in the ileum of mice sampled during the vivarium's 128 dark-phase as compared to the light-phase, which correspond to periods of food 129 consumption and resting, respectively (Extended Data Fig. 7a ). Due to the ad libitum 130 7 inhibitory axis and to reduce the noise created by feeding during the resting period, we 133 restricted food availability for two weeks to alternating 12h cycles of feeding and fasting. 134
To dissociate the effects of light/dark cycles from time of feeding, food was available to 135 a group of mice only during the dark-phase (night-fed mice, ZT12-ZT0/6PM-6AM), while 136 another group had food available only during the light-phase (day-fed mice, ZT0-137 ZT12/6AM-6PM). Using this scheme, we observed more VIP in the portal vein, but not 138 in the peripheral blood, after 6h of food availability when compared to mice fasted for 139 6h, regardless of whether mice were fed during the light phase (ZT 6) or during the dark 140 phase (ZT 18) (Extended Data Fig. 7b ,c). In turn, the frequency of IL-22 + CCR6 + ILC3 141 was reduced during the periods of food consumption (at 6h of feeding) relative to fasting 142 periods (fasted for 6 h), independently of light-dark cycles (Fig. 3a,b) . 143
Using the mixed bone marrow chimeric mice, we observed among the Vipr2 +/+ 144 CCR6 + ILC3 a reduced frequency of IL-22 + cells at 6h after start of food consumption 145 (ZT 18) when compared to mice fasted for 6h (ZT 6) (Fig 3c and 3d) . In contrast, there 146 was no difference in frequency of IL-22 + cells in the Vipr2 −/− CCR6 + ILC3 population with 147 or without feeding. This is consistent with VIPR2 signaling-dependent inhibition of IL-22 148 production in CCR6 + ILC3 following food intake. This conclusion was further supported 149 by the observed reduction in the frequency of IL-22 + CCR6 + ILC3 at 6h following 150 intragastric delivery of a liquid test diet, but not control saline, during the light-phase 151 period (ZT1-ZT7) (Fig 3e,f) . Furthermore, DREADD-mediated inhibition of VIPen 152 abrogated the effect of the test diet on ILC3 ( Fig. 3e and 3f) . These results suggest a 153 fast and dynamic temporal control of intestinal CCR6 + ILC3 function promoted by food 154 intake-mediated activation of VIPen and VIPR2. 155 8 Because IL-22 acts on intestinal epithelial cells to regulate barrier functions, 156
including their interactions with commensal microbiota, we next examined whether the 157 neuroimmune inhibitory circuit promoted by food consumption influences host-microbial 158
interactions. There was elevated RegIIIg mRNA expression in the IECs in mice fasted 159 for 12h as compared to those fed during that time frame. In parallel, food consumption 160 had a striking effect on the morphology of the ileal epithelium-associated segmented 161 filamentous bacteria (SFB) (Fig. 4a -c and Extended Data Fig. 7d,e ). SFB attached to 162
IECs had long segmented filaments after 12h of food consumption, independently of 163 light/dark cycles. However, in the ileum of mice fasted for 12h, independently of light-164 cycle, epithelium-associated SFB had few segments and were stubble-like. Short-term 165 blockade with a-IL-22 reduced RegIIIg mRNA expression in the IECs of mice during 166 fasting, but not during feeding (Fig. 4c ), and prevented control of SFB growth upon food 167 restriction ( Fig. 4d ). In ILC3 D Vipr2 mice, which have increased IL-22 production, SFB 168 failed to form segmented filaments even after 12h of food consumption ( Fig. 4e,f) . 169
These results suggest that VIPen regulate growth of the commensal microbiota by 170 modulating cryptopatch-associated ILC3 in response to food consumption. 171
As IL-22 was recently shown to regulate lipid metabolism 8 , at least in part by 172 controlling genes involved in lipid transport, we examined the role of the VIPen-ILC3-IL-173 22 circuit in lipid absorption. Mice were adapted for 2 weeks to 12h restricted feeding 174 during light or dark cycles and were then gavaged with 3 H-triolein following feeding or 175
fasting. Mice that had been fed for 12h absorbed more of the triglyceride than mice 176 fasted for 12h, although there was some effect of circadian regulation (light/dark 177 adaptation) (Extended Data Fig. 7f ,g). Expression of mRNAs for proteins associated 9 with fatty-acid/lipid uptake and transport (e.g. Fabp2) was lower in IECs from mice that 179 were food-restricted for 12h compared to fed mice ( Fig. 4g ), in inverse relationship to 180
RegIIIg mRNA (Fig 4c) . Moreover, short-term treatment with a-IL-22 during the fasting 181 period reverted the expression of lipid transporters in IEC and 3 H-triolein absorption to 182 amounts comparable to those observed with fed mice (Fig 4g,h) . 183
The effect of food intake on IEC-dependent lipid absorption was dependent on 184
VIPen inhibition of ILC3, since expression of lipid transporter mRNAs, 3 H-triolein 185 absorption, and concentrations of circulating plasma triglycerides were substantially 186 reduced in ILC3 D Vipr2 when compared to WT mice after 12h of feeding (ZT 0) (Figures 187 4i-k). Finally, continuous intragastric delivery of a liquid test diet for 6h during the light 188 phase period led to an increase in serum triglycerides, which was blocked by DREADD-189 mediated inhibition of VIPen ( Fig. 4l ). 190
These results reveal an important neuro-immune circuit in which feeding-activated 191
VIPen antagonize microbiota-dependent CCR6 + ILC3 function, resulting in reduced IL-192 22 production and increased efficiency of lipid absorption. The benefit of greater nutrient 193 acquisition comes at the expense of reduced barrier function, illustrated by susceptibility 194 to enteropathic bacteria and rapid growth of epithelial-associated commensal SFB. 195 Whether the host derives benefit from the reduced anti-microbial activity is unclear, 196 although it may enable bacteria-dependent generation of essential metabolites 26 and 197 vitamins that would be readily absorbed. Since enteric glial cells (EGCs) can secrete 198 factors that act as activators of ILC3 functions 10 , it will be important to determine how 199
VIPen and EGCs coordinate antagonistic signals to promote efficient modulation of 200 ILC3-mediated intestinal barrier functions, and also how neural development-associated 201 factors expressed by ILC3 (e.g. Cntn1, Sema3d, Bmp2) contribute to formation of 202 neuro-immune cell units in cryptopatches/ILFs. 203
The mechanism by which the presence of food in the intestinal lumen is sensed and 204 promotes VIPen activation is still unclear, and microbial 27,28 , nutritional 4 or mechanical 205 stimuli 29 , acting peripherally or by way of the central nervous system, may be 206 responsible for this. The VIP system has been implicated in circadian regulation 207 centrally, as VIPR2 is required for expression of the core clock genes in the 208 suprachiasmatic nuclei of the hypothalamus, and in the periphery, with circadian 209 oscillation of IL-5 and IL-13 production by ILC2 and feeding-associated eosinophil 210 recruitment in lung and gut mucosa 30, 31 . While our study highlights the importance of 211 food intake in regulating the VIPen, there is also a light-dependent contribution to the 212 efficiency of lipid absorption, as there was only a partial effect when the feeding cycle 213 was reversed. We therefore cannot rule out an additional role for central or peripheral 214 clock functions independent of VIPen and ILC3. 215
Our results suggest that disturbances in feeding schedules could reduce intestinal 216 barrier functions and promote dysbiosis and at the same time contribute to metabolic 217 inbalance by chronic activation of VIPen. Moreover, enteropathogens may hijack this 218 neuro-immune circuit and reduce intestinal barrier functions, facilitating intestinal 219 colonization. In these scenarios, VIPR2 inhibitors may be valuable therapeutic tools to 220 reduce lipid absorption or enforce the barrier during acute gastrointestinal infections. C57Bl/6 mice were obtained from Taconic Farm. All transgenic mice were bred and 430 maintained in the animal facility of the Skirball Institute (New York University School of 431 Medicine) in specific pathogen-free conditions. hM3Dq fl-stop-fl mice (CAG-LSL-Gq-432 DREADD, Jax #026220), hM4Di fl-stop-fl mice (CAG-LSL-Gi-DREADD, Jax #026219), 433 VIP IRES-Cre mice (B6J.Vip-IRES-Cre, Jax #031628) and CD45.1 mice (B6.SJL-Ptprca 434 Pepcb/BoyJ, Jax# 002014) were purchased from Jackson Laboratories. Rorc(gt) EGFP/+ 435 and Rorc Cre mice were generated in our laboratory and previously described 14, 22 . Vipr2 -436 /mice (Jax# 031332) were purchased from Jackson Laboratories and were maintained 437 in a CD45.2 background or were bred with CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice, 438 which subsequently generated Vipr2 -/-CD45.1/2 mice and WT CD45.1 littermates. 439
Conditional VIPR2 knockout (Vipr2 fl/fl ) mice were generated using CRISPR-Cas9 440 
Food restriction protocol 491
For a period of two weeks, food was made available to mice only for 12h per daily cycle. Mice 492 were kept in two different regimens: Dark-phase fed mice, with food being available between 6 493 PM -6AM (ZT 12->ZT 0); and light-phase fed, with food being available between 6 AM -6PM 494 (ZT 0->ZT 12). To avoid littering, at the beginning of the fasting period of each regimen, mice 495 were transferred to a clean cage containing alpha cellulose clean bedding 496 (Shepherd's™ALPHA-dri). Mice were provided with free access to water. 497 498
Gavage of Liquid Test Diet 499
Dry powder micro stabilized rodent liquid diet (Test Diet, LD 101) was blended (mechanical 500 blender) vigorously for 30 seconds in saline (NaCl 0.9%) at 0.5g/mL. Mice were gavaged with 501 400ul of this solution using a polyurethane feeding tube (16ga x 38mm, FTPU-16-38-50, 502 INSTECH) every 45 min for 6 h. 503 504
Generation of bone marrow VIPR2 +/+ /VIPR2 -/chimeric reconstituted mice 505
Bone marrow mononuclear cells were isolated from CD45.1 VIPR2 +/+ and CD45.2 (or 506 CD45.1/2) VIPR2 -/mice by flushing the long bones. Red blood cells were lysed with ACK 507
Lysing Buffer and the remaining cells were resuspended in PBS for injection in at a 1:1 ratio 508 (WT:VIPR2 KO). 4×10 6 cells were injected intravenously into 6 week old CD45.1/2 (CD45.2) 509 mice that were irradiated 4h before reconstitution using 1000 rads/mouse (2x500rads, at an 510 interval of 3h, at X-RAD 320 X-Ray Irradiator). To deplete intestinal ILC3, one day after the 511 bone marrow transfer, mice were treated with InVivoMAb anti-mouse Thy1. with Draq-7 (R&D Systems) or 4′,6-diamidino-2-phenylindole (DAPI, ThermoFisher). Images 554 were acquired using a Zeiss LSM 710 confocal (Carl Zeiss). The imaging data were processed 555 and analyzed using Image J software (NIH, Bethesda, MD). Imaris software version 9.0.1 556 (Bitplane; Oxford Instruments) was used to generated reconstructed 3D images. 557 558
Isolation of Lamina Propria Lymphocytes (LPLs) from the small intestine 559
Whole small intestine or the ileum (distal 14cm of the small intestine) was dissected from mice. 560
Mesenteric fat tissue and Peyer's patches were carefully removed from these tissues. 561
Intestinal tissue was opened and extensively cleaned of fecal matter. Following, this tissue was 562 sequentially treated with HBSS 1X (1 mM DTT) at 37°C for 10 min with gentle shaking 563 (200rpm), and twice with 5 mM EDTA at 37°C for 10 min to remove epithelial cells. The EDTA 564 fraction (epithelial cell-enriched) was filtered, centrifuged and suspended in Trizol for further 565 25 RNA isolation. The remaining tissue was then minced with a scissor and dissociated in RPMI 566 containing 10% FBS, Dispase (0.05 U/ml; Worthington), collagenase (1 mg/ml collagenase II; 567 Roche) and DNase I (100 μg/ml; Sigma) at constant shaking at 37°C for 45 min (175rpm). The 568 digested tissue was then filtered through a 70µm strainer to remove large debris. Viable were isolated from small intestine LPLs of C57BL/6 mice using the ARIA II FACS Sorter (BD 576 Biosciences). ILC3 were cultured at 37 o C in flat bottom 96 well plates (10 4 cells/well) in RPMI 577 supplemented with 10% heat-inactivated FBS (Hyclone), 50 U penicillin-streptomycin 578 (Hyclone), 2 mM glutamine (Hyclone), 10mM HEPES (Hyclone), 1mM sodium pyruvate 579 (Hyclone) and 50 μM β-mercaptoethanol (Gibco). ILC3 were stimulated with IL-23 (100pg/mL, 580 R&D systems) and/or VIPR2 ligands (BAY-559837: 1-100nM, and VIP: 1nM, TOCRIS) for 16h 581 (37 o C), washed, incubated in complete media in the presence of Golgi Plug (BD Bioscience) 582 for 4h (37 o C), and stained for membrane extracellular markers in Staining Buffer (PBS FBS2% 583 EDTA 5mM) and for intracellular markers using Cytofix/Cytoperm buffer set following 584 manufacturer's protocol (BD Biosciences). Acquisition of cytometric parameters was 585 performed on an LSRII (BD Biosciences). All data were analyzed using FlowJo Software 586
Version 10 (Tree Star). 587 588 26
Antibodies for intracellular staining and flow cytometry 589
Live/dead fixable blue (ThermoFisher) or DAPI (ThermoFisher) were used to exclude dead 590 cells. The following monoclonal antibodies were purchased from eBiosciences, BD 591 Pharmingen or BioLegend: CD3, CD45.1, CD45.2, TCRβ, CD11c, CD14, CD19, TCRb, TCRg, 592 NK1.1, CD127, CD90.2, CCR6, Sca-1 and IL-22. For cytokine analysis, cells were incubated 593 for 4 hours at 37C in RPMI with 10% FBS and GolgiPlug (BD). Cells were stained for surface 594 markers before fixation and permeabilization, and then subjected to intracellular cytokine 595 staining for IL-22 according to the manufacturer's protocol (Cytofix/Cytoperm buffer set from 596
BD Biosciences). Flow cytometric analysis was performed on an LSR II (BD Biosciences) or an 597
Aria II (BD Biosciences) and analyzed using FlowJo software version 10 (Tree Star). 598 599
Blood collection 600
Peripheral and portal vein blood were collected under general anesthesia (Ketamine 601 100mg/Kg, Xylazine 15mg/Kg). Peripheral blood was collected through orbital venous plexus 602 bleeding with a glass capillary in a tube containing EDTA (25mM) as an anticoagulant. Plasma 603 was collected after centrifugation of the collected sample and frozen until processing. Surgery 604 was performed to collect blood from the portal vein, which drains the gastrointestinal tract. 605
Briefly, after laparotomy, the portal vein was localized and the blood was collected with a 606 syringe. Portal vein blood was processed following the same protocol above for peripheral 607 blood. 608 609 Tissue processing for ELISA 610
Distal Ileum (6 cm from the ileal-cecal junction) or the Large intestine (Cecum + 3 cm of the 611 proximal colon) were collected and extensively washed to clean out fecal matter. The samples 612 were weighed and, using a tissue homogenizer, extracted in PBS Tween 0.1% (with protease 613 inhibitor) and centrifuged to remove tissue debris. The supernatant was frozen until 614 measurement of VIP concentrations in the tissue. 615
616

ELISA for Vasoactive Intestinal Peptide 617
VIP content was measured in the blood plasma or homogenized tissue following 618 manufacturer's recommendations (EIAM-VIP-1, RayBiotech). 619 620
Measurement of plasma concentration of triglycerides 621
Peripheral blood was collected as described above and plasma was used to quantify 622 triglyceride concentrations following manufacturer's recommendations (Sigma-Aldrich, 623 MAK266). 624 625
Scanning Electron Microscopy 626
Scanning Electron Microscopy was performed on 1-1.5 cm pieces from terminal ileum 627 (2cm above the ileal-cecal junction). Intestine was cut open and washed to remove fecal 628 matter, pinned in dental wax and fixed for 2h with a 0.1M sodium cacodylate buffer (CB, 629 pH 7.4) containing 2.5% glutaraldehyde and 2% paraformaldehyde. Samples were post 630 fixed in 1% OsO4 for 2 hours, dehydrated in ethanol, and critical point dried using Continuation Figure 2 . Vehicle: 6, CNO: 7. **P<0.01 (t-test). j, Normalized epithelial Reg3γmRNA at 24h following treatment with vehicle or CNO. Vehicle: 7, CNO: 6. *P<0.05 (t-test). Data representative of three independent experiments. k, l, Dissemination of C. rodentiumto the (k) spleen and (l) liver in Vip IRES-Cre hM3Dq flstop-fl/+ mice treated with vehicle or CNO (1mg/Kg, daily) for 4 days post-intragastric infection with 2x10 9 CFU. Log 10 Colony Forming Units (CFU) of C. rodentium 9 days post-oral innoculation (9 d.p.i.). Dotted line: limit of detection. ***P=0.0009 and ****P<0.0001, (Mann-Whitney test). Vehicle: n=11 (Positive for C. rodentium: spleen: 6/11, liver: 8/11), CNO: n=9 (Positive for C. rodentium: spleen and liver: 9/9). Data representative of two independent experiments. m, Survival rates for C. rodentium-infected Vip IRES-Cre hM3Dq Representative FACS plot (a) and summaries (b) indicating IL-22 expression among CCR6 + ILC3 from the ileum of mice 6h after feeding or fasting, at ZT6 and ZT18. N=5, *P<0.05 (t-test). Data are representative of two independent experiments. c, IL-22 expression by CCR6 + ILC3 from the ileum of CD45.1 Vipr2 +/+ :CD45.2 Vipr2 −/− bone marrow chimeric mice 6h after fasting (fasted, ZT 6) and 6h after feeding (fed, ZT 18). n=7, *P<0.05 (paired t-test) . Data are representative of two independent experiments. d, Ratio of IL-22-expressing cells, relative to Figure 3c , among CCR6 + ILC3 from the ileum of CD45.1 Vipr2 +/+ :CD45.2 Vipr2 −/− bone marrow chimeric mice 6h after fasting (Fasted, ZT 6) and 6 hours after feeding (Fed, ZT 18). n=7, *P<0.05 (t-test) . e, f, Representative FACS plot (e) and summaries (f) indicating IL-22 expression in CCR6 + ILC3 from the ileum of Vip IRES-Cre hM4Di flstop-fl/+ mice (DREADD for VIPen inhibition). Mice were treated with vehicle or CNO (1mg/Kg) and 30 minutes later were fed by intragastric administration of saline (0.4 mL each 45 min, for 6 h) or Liquid Test Diet (500 mg/mL, 0.4mL each 45 minutes, for 6 h). N=4, **P<0.01 (t-test). Figure 4 . Dynamic regulation of commensal bacterial growth and lipid absorption by feedingdependent VIP production . a, b, Representative scanning electron microscopy (SEM) images (a) of epithelium-associated commensal SFB in the ileum of mice 12h after fasting or feeding at the end of the darkphase (ZT 0) and the light-phase (ZT 12) and (b) measurements of SFB filament lengths. N=3, ****P<0.001 (ttest). c, Normalized epithelial Reg3γ mRNA expression in the ileum of mice treated with IgG or α-IL-22 (10mg/Kg) during the feeding period (Fed for 12h: Treated from ZT 12->ZT 0) or during the fasting period (Fasted for 12h: Treated from ZT 0->ZT 12). Data pooled from 2 independent experiments: Fed IgG1: N=8, Fed α-IL-22: N=8, Fast IgG1: N=8, Fed α-IL-22: N=7, *P<0.05 and **P<0.01 (t-test). d, SFB length in the ileum of mice treated with IgG or α-IL-22 (10mg/Kg) during the feeding period (Fed for 12h: ZT 12->ZT 0) or during the fasting period (Fast for 12h: ZT 0->ZT 12). N= 3, ****P<0.001 (t-test) . e,f, Representative (e) SEM images of epithelium-associated SFB in the ileum of WT and ILC3 ΔVipr2 mice fed for 12h and (f) measurement of bacterial filament lengths. N= 3, ****P<0.001 (t-test). g, Normalized epithelial mRNA expression of Fabp2 in the ileum of mice treated with IgG or α-IL-22 (10mg/Kg) during the fasting period (Fasted for 12h: Treated from ZT 0->ZT 12). Data pooled from 2 independent experiments: Fed IgG1: N=8, Fed α-IL-22: N=8, Fast IgG1: N=8, Fed α-IL-22: N=7. *P<0.05 and **P<0.01 (t-test). h, Plasma 3 H CPM (counts per minute) in 12h fasted mice after gavage with 3 H-triolein (1uCi/mice in 200ul of 20% Intralipid). Mice were treated with IgG or α-IL-22 (10mg/Kg) during the fasting period (Fasted for 12h: Treated from ZT 0->ZT 12). Data representative of 2 independent experiments. N=4, ***P<0.001 (two-way ANOVA). i, j, Normalized epithelial mRNA expression of Fabp2 and Cd36 (i) and plasma triglyceride content (j) in 12h fed WT (N=5) and ILC3 ΔVipr2 (N=4) mice. *P<0.05 and **P<0.01 (t-test). k, Plasma 3 H CPM in 12h fed WT (N=3) and ILC3 ΔVipr2 (N=3) mice after gavage with 3 Htriolein. ***P<0.001, (two-way ANOVA). l, Plasma triglyceride content in Vip IRES-Cre hM4Di fl-stop-fl/+ mice (DREADD for VIPen inhibition) after gavage with Saline (0.4 mL/each 45 minutes, for 6 hours) or Liquid Test Diet (500 mg/mL, 0.4mL/each 45 minutes, for 6 hours). Vehicle: N=5, CNO: N=4. **P<0.01, (t-test).
